AngioDynamics Receives Expanded FDA Clearance for AngioVac

AngioDynamics Receives Expanded FDA Clearance for AngioVac

ALBANY, N.Y., March 11, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO),
a leading provider of innovative, minimally invasive medical devices for
vascular access, surgery, peripheral vascular disease and oncology, today
announced the U.S. Food and Drug Administration (FDA) cleared an expanded
indication for its AngioVac cannula for venous drainage during extracorporeal
bypass for up to six hours to include removal of fresh, soft thrombi or
emboli.

"Since its introduction to our portfolio in October 2012, the AngioVac cannula
and circuit has shown strong market acceptance across the U.S. due to its
ability to improve patient outcomes and reduce the cost of treatment," said
John Soto, Executive Vice President and Chief Commercial Officer. "The
expanded FDA clearance, which includes the removal of fresh, soft thrombi or
emboli during extracorporeal bypass, makes this a more powerful tool for
physicians in the U.S., where an estimated 1 million people are affected by
venous thromboembolic disease (VTE)."

The AngioVac cannula and circuit, when combined with other manufacturers'
filters, pumps and return cannula, comprise an extracorporeal bypass circuit
that facilitates drainage, filtration and reinfusion of blood for up to six
hours. The AngioVac Cannula has a proprietary balloon-actuated, expandable,
funnel-shaped distal tip to enhance flow, prevent clogging of the cannula and
facilitate en bloc removal of undesirable intravascular material such as
fresh, soft thrombi or emboli.

Venous thromboembolic events are a leading cause of morbidity and mortality,
and the annual number of VTE-related deaths has been estimated at more than
300,000 across the U.S. Pharmacomechanical therapies and catheter-directed
thrombolysis offer many benefits over the current standard of care,
anticoagulant therapy; however, these treatments can cause major bleeding
complications and a significant number of patients have contraindications.
Removal of undesirable intravascular material may provide an effective
alternative, minimizing the potential risks and comorbidities associated with
these treatments.

"Products like AngioVac represent our commitment to pioneering new
technologies that not only provide a clinical benefit to our customers, but
also economic value," said Joseph M. DeVivo, AngioDynamics' President and CEO.
"This expanded indication allows us to grow awareness of the significant
morbidity and mortality associated with VTE and the role AngioVac can play in
meeting the significant need it presents."

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive
medical devices used by professional healthcare providers for vascular access,
surgery, peripheral vascular disease and oncology. AngioDynamics' diverse
product lines include market-leading ablation systems, fluid management
systems, vascular access products, angiographic products and accessories,
angioplasty products, drainage products, thrombolytic products and venous
products. More information is available at www.AngioDynamics.com.

Trademarks

AngioDynamics, the AngioDynamics logo and AngioVac are trademarks and/or
registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.

Safe Harbor

This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements regarding
AngioDynamics' expected future financial position, results of operations, cash
flows, business strategy, budgets, projected costs, capital expenditures,
products, competitive positions, growth opportunities, plans and objectives of
management for future operations, as well as statements that include the words
such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes,"
"seeks," "estimates," "optimistic," or variations of such words and similar
expressions, are forward-looking statements. These forward looking statements
are not guarantees of future performance and are subject to risks and
uncertainties. Investors are cautioned that actual events or results may
differ from AngioDynamics' expectations. Factors that may affect the actual
results achieved by AngioDynamics include, without limitation, the ability of
AngioDynamics to develop its existing and new products, technological advances
and patents attained by competitors, future actions by the FDA or other
regulatory agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials, overall economic
conditions, the results of on-going litigation, the effects of economic,
credit and capital market conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, the effects on
pricing from group purchasing organizations and competition, the ability of
AngioDynamics to integrate purchased businesses, including Navilyst Medical
and its products, R&D capabilities, infrastructure and employees as well as
the risk factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the year ended
May 31, 2013. AngioDynamics does not assume any obligation to publicly update
or revise any forward-looking statements for any reason.

CONTACT: Company Contact:
         AngioDynamics Inc.
         Mark Frost, CFO
         (800) 772-6446 x1981
         mfrost@AngioDynamics.com
        
         Investor Relations Contacts:
         EVC Group, Inc.
         Michael Polyviou/Robert Jones
         (212) 850-6020; (646) 201-5447
         mpolyviou@evcgroup.com; bjones@evcgroup.com
        
         Media Contact:
         EVC Group, Inc.
         Dave Schemelia
         (646) 201-5431
         dave@evcgroup.com
 
Press spacebar to pause and continue. Press esc to stop.